Severe atopic dermatitis associated with learning disability in children: JAMA

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-04-17 08:45 GMT   |   Update On 2021-04-17 08:47 GMT

USA: Atopic dermatitis (AD) in children is associated with learning problems and children having more severe skin disease should undergo screening and treatment for any learning difficulties, finds a recent study in the journal JAMA Dematology.Recent population-based data have shown association between atopic dermatitis and learning disability (LD) in children, but the association between...

Login or Register to read the full article

USA: Atopic dermatitis (AD) in children is associated with learning problems and children having more severe skin disease should undergo screening and treatment for any learning difficulties, finds a recent study in the journal JAMA Dematology.

Recent population-based data have shown association between  atopic dermatitis and learning disability (LD) in children, but the association between AD severity and LD is not known. Joy Wan, University of Pennsylvania Perelman School of Medicine, Philadelphia, and colleagues aimed to evaluate the association of AD severity with learning problems in children with AD.

For the purpose, the researchers conducted cross-sectional study that analyzed data of US participants enrolled in the Pediatric Eczema Elective Registry (PEER) between November 1, 2004, and November 30, 2019. Participants were children aged 2 to 17 years at registry enrollment with physician-confirmed diagnosis of AD and had completed 10 years of follow-up in PEER.

The severity of AD was measured by both the Patient-Oriented Eczema Measure (POEM) score and self-report. The POEM scores ranged from 0 to 28, with strata of clear or almost clear skin (0-2), mild (3-7), moderate (8-16), severe (17-24), and very severe (25-28). Self-reported AD severity was categorized as clear skin or no symptoms, mild, moderate, or severe.

Main outcome was learning disability diagnosed by a health care practitioner, as reported by the participants or their caregivers. 

Key findings of the study include:

  • Among the 2074 participants with AD (1116 girls [53.8%]), 169 (8.2%) reported a diagnosis of an LD.
  • Children with an LD vs those without an LD were more likely to have worse AD severity, as measured by the median (IQR) total POEM score (5 vs 2), POEM severity category (moderate AD: 50 of 168 [29.8%] vs 321 of 1891 [17.0%]; severe to very severe AD: 15 of 168 [8.9%] vs 85 of 1891 [4.5%]); and self-report (moderate AD: 49 of 168 [29.2%] vs 391 of 1891 [20.7%]; severe AD: 11 of 168 [6.5%] vs 64 of 1891 [3.4%]).
  • In multivariable logistic regression models adjusted for sex, age, race/ethnicity, annual household income, age of AD onset, family history of AD, and comorbid conditions, participants with mild AD (odds ratio [OR], 1.72), moderate AD (OR, 2.09), and severe to very severe AD (OR, 3.10) on the POEM were all significantly more likely to have reported an LD than those with clear or almost clear skin.

"Our study found that worse AD severity was associated with greater odds of reported LD, independent of socioeconomic characteristics, AD onset age, and other related disorders," wrote the authors. "Although additional prospective and mechanistic studies are needed to clarify the association of AD with learning, the findings suggest that children with more severe AD should be screened for learning difficulties to initiate appropriate interventions that can mitigate the consequences of an LD."

Reference:

The study titled, "Association of Atopic Dermatitis Severity With Learning Disability in Children," is published in the journal JAMA Dermatology.

DOI: https://jamanetwork.com/journals/jamadermatology/article-abstract/2778390

Tags:    
Article Source : JAMA Dermatology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News